Hank’s Law

02/23/2026

The nose knows!

Hemangiosarcoma is an aggressive cancer that often goes undetected until it's too late. But thanks to researchers at the Working Dog Center of the University of Pennsylvania, dogs are being trained to smell this disease. By identifying a unique "scent signature," these amazing dogs are helping scientists move toward a level of early detection for that veterinary diagnostics have yet to achieve.

Find out more and how you can support below 👇

02/20/2026

“EGFR and HER2 and their overexpression correlates with poor prognosis and limited survival, as well as tumor growth and encouraging metastases in both human and dog cancers.

These proteins bind together on the surface of the tumor cell and give very strong activation signals that go to the nucleus. What do they tell the tumor cell to do? They tell it to grow, to divide, and to metastasize.

In very aggressive cancers, there’s lots of HER2 and EGFR expressed on the surface of the tumor, and tumors that express this family of proteins have a very poor prognosis.

What we do is trick the immune system into making antibodies and T cells that start to attack the tumor cell, actually proteins on the tumor cell specifically.”

-Prof Mark Mamula
EGFR/HER2 Yale Vaccine Update 2026

--
🔗 learn more about the latest findings from the EGFR HER2 vaccine immunotherapy trial and how it can make a difference for pups!

https://www.ccralliance.org/post/egfr-her2-yale-vaccine-update

02/18/2026

In this episode, Amy sits down with Marti Bortz and Toni Turk. They are both Breast Cancer Survivors. In separate interviews, these women share their stories...

02/17/2026

02/15/2026

02/04/2026

Today is World Cancer Day, an international awareness day that brings the global community together to advance progress against cancer.

Sarcoma is rare, complex, and often overlooked, yet it affects hundreds of thousands of people around the world each year. Meaningful progress against sarcoma depends on sustained research, funding, and global collaboration. Since 2000, SFA has invested more than $27 million in sarcoma research in the United States and across 13 countries to help improve outcomes for people affected by sarcoma.

On World Cancer Day, and every day, SFA continues to be guided by a bold and unwavering vision: a world where no one dies from sarcoma.

02/04/2026

A total of 30 modifiable risk factors account for almost 40% of new cancer cases globally, a landmark study from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) has found.